Skip to main content
Top
Published in: Diabetologia 8/2008

01-08-2008 | Short Communication

Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2

Authors: A. J. K. Williams, R. J. Aitken, M. A.-M. Chandler, K. M. Gillespie, V. Lampasona, P. J. Bingley

Published in: Diabetologia | Issue 8/2008

Login to get access

Abstract

Aims/hypothesis

To further our understanding of antigen presentation by HLA class II molecules, we have examined the influence of HLA class II genotype on expression of autoantibodies to islet antigen-2 (IA-2A).

Methods

HLA class II genotype and IA-2A were determined within 3 months of diagnosis in 618 patients with type 1 diabetes (median age 11 years [range 0.7–20.9]). Antibodies to the juxtamembrane region of IA-2 were measured by a radiobinding assay in 481 of 484 IA-2A-positive patients.

Results

IA-2A prevalence was highest in patients carrying at least one HLA-DRB1*04-DQA1*0301 (385 of 450; 86%), DRB1*07-DQA1*(0201 or 0301) (58 of 64; 91%) or DRB1*09-DQA1*0301 haplotype (18 of 19; 95%). Multiple regression showed that IA-2A were strongly associated with the number of these haplotypes carried; only 69 of 132 (52%) patients carrying none of these haplotypes had IA-2A, compared with 322 of 391 (82%) patients with one and 93 of 95 (98%) with two of these haplotypes (p < 0.001). IA-2 juxtamembrane antibodies were less frequent in IA-2A-positive patients with one (35%) or two (36%) DRB1*03-DQB1*02 or DRB1*07-DQB1*02 haplotypes than in those negative for these haplotypes (52%) (p = 0.002), but showed an independent positive association with IA-2A level (p < 0.001).

Conclusions/interpretation

HLA class II alleles strongly influence the prevalence of IA-2A. The high IA-2A prevalence in patients carrying DRB1*04, DRB1*07 and DRB1*09 alleles in linkage disequilibrium with DQA1*0301 or the closely related DQA1*0201 suggests the humoral response to IA-2 may be driven by HLA-DQA1 genes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Genovese S, Bonfanti R, Bazzigaluppi E et al (1996) Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39:1223–1226PubMedCrossRef Genovese S, Bonfanti R, Bazzigaluppi E et al (1996) Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia 39:1223–1226PubMedCrossRef
2.
go back to reference Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMedCrossRef Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMedCrossRef
3.
go back to reference Naserke HE, Ziegler AG, Lampasona V, Bonifacio E (1998) Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 161:6963–6969PubMed Naserke HE, Ziegler AG, Lampasona V, Bonifacio E (1998) Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 161:6963–6969PubMed
4.
go back to reference Bingley PJ, Bonifacio E, Mueller PW (2003) Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52:1128–1136PubMedCrossRef Bingley PJ, Bonifacio E, Mueller PW (2003) Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52:1128–1136PubMedCrossRef
5.
go back to reference Lambert AP, Gillespie KM, Thomson G et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043PubMedCrossRef Lambert AP, Gillespie KM, Thomson G et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043PubMedCrossRef
6.
go back to reference Andersson G (1998) Evolution of the HLA DR region. Front Biosci 27:d739–d745 (Review) Andersson G (1998) Evolution of the HLA DR region. Front Biosci 27:d739–d745 (Review)
7.
go back to reference Huck C, Endl J, Walk T et al (2001) HLA-DR53 molecules restrict glutamic acid decarboxylase peptide presentation to T cells of a Type I diabetes patient: specification of the trimolecular HLA-peptide/T cell receptor complex. Diabetologia 44:70–80PubMedCrossRef Huck C, Endl J, Walk T et al (2001) HLA-DR53 molecules restrict glutamic acid decarboxylase peptide presentation to T cells of a Type I diabetes patient: specification of the trimolecular HLA-peptide/T cell receptor complex. Diabetologia 44:70–80PubMedCrossRef
8.
go back to reference Lee KH, Wucherpfennig KW, Wiley DC (2001) Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2:501–507PubMedCrossRef Lee KH, Wucherpfennig KW, Wiley DC (2001) Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2:501–507PubMedCrossRef
9.
go back to reference Kawasaki E, Sera Y, Fujita N et al (2001) Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes. J Autoimmun 17:323–331PubMedCrossRef Kawasaki E, Sera Y, Fujita N et al (2001) Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes. J Autoimmun 17:323–331PubMedCrossRef
10.
go back to reference Redondo MJ, Babu S, Zeidler A et al (2006) Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 91:1705–1713PubMedCrossRef Redondo MJ, Babu S, Zeidler A et al (2006) Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 91:1705–1713PubMedCrossRef
Metadata
Title
Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2
Authors
A. J. K. Williams
R. J. Aitken
M. A.-M. Chandler
K. M. Gillespie
V. Lampasona
P. J. Bingley
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-1047-3

Other articles of this Issue 8/2008

Diabetologia 8/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine